POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy
POZ uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.
Richard Jefferys
This is what Angela Kashuba said when the tenofovir gel results were presented- 'In early development, Tenofovir was thought not to be potent against HSV-2 because of its in vitro EC50 of 240 micromolar or 10,000 nanograms per mil. This concentration is difficult to achieve taking a drug orally but is very easy to achieve taking a drug topically.' Full transcript & video is here - globalhealth.kff.org/AIDS2010/July-20/Safety-and-Effectiveness.aspx
December 15, 2010 • New York